A Phase 1/2 Open-Label First-in-Human Study to Evaluate the Safety and Anti-Tumor Activity of FS118 a LAG-3/PD-L1 Bispecific Antibody in Patients with Advanced Malignancies

A Phase 1/2 Open-Label First-in-Human Study to Evaluate the Safety and Anti-Tumor Activity of FS118 a LAG-3/PD-L1 Bispecific Antibody in Patients with Advanced Malignancies
Enrolling By Invitation
18 years - 99 years
All
Phase N/A
10 participants needed
1 Location

Brief description of study

This research study is for those with you have advanced cancer. This research study is designed to learn more about the safety and effectiveness of FS118, an investigations drug given to individuals who have been diagnosed with advanced cancer.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Advanced Malignancies,Malignancies
  • Age: 18 years - 99 years
  • Gender: All


Updated on 04 Aug 2024. Study ID: 849099
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research